Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are ...

GLP-1-based therapy: incretin mimetics (GLP-1 analogues) and incretin enhancers (DPP-4 inhibitors) are now available for the treatment of Type 2 diabetes. Initial combination therapy with a DPP-4 ...

Patients with MASLD and diabetes from 130 Veterans Health Administration hospitals and associated ambulatory clinics who initiated a GLP-1 RA or dipeptidyl peptidase 4 inhibitor (DPP-4i ...

A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

Dipeptidyl peptidase 4 (DPP-4) inhibitors block the degradation of the body's own endogenous GLP-1, as well as other peptide hormones such as glucose-dependent insulinotropic peptide (GIP).

Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking ...

dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide 1 (GLP-1) agonists. Among these medications, sulfonylureas are the oldest and most widely used; however, both DPP-4 inhibitors ...

SGLT-2 inhibitors were associated with the lowest risk for incidental dementia relative to DPP-4 inhibitors and GLP-1RAs in type 2 diabetes.

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing ...

GLP-1 receptor agonists do not affect cardiovascular, kidney, or safety outcomes regardless of SGLT2 inhibitor use in patients with type 2 diabetes.